Among those with CAD, both rosuvastatin and atorvastatin are similarly effective regarding the combination of all-cause death, MI, stroke, or any coronary revascularization over 3 years, according to ...

A head-to-head comparison of two popular lipid-lowering medications suggests that rosuvastatin may be a better option than atorvastatin when it comes to decreasing the risk of all-cause mortality and ...

Few real-world studies have investigated the risks of hematuria and proteinuria associated with rosuvastatin use. Rosuvastatin may increase the risk of hematuria, proteinuria, and kidney failure, ...

Rosuvastatin tied to cardiovascular and mortality benefits but also higher risk for type 2 diabetes. HealthDay News — There are small but important differences in risk for some clinical outcomes ...

In a head-to-head test of two popular cholesterol-lowering statin drugs — Lipitor and Crestor — both medications worked equally well. Lipitor (atorvastatin) and Crestor (rosuvastatin) both effectively ...

Efficacy of switching statin therapy from generic simvastatin was examined in a VA population. Ezetimibe/simvastatin was more potent than atorvastatin or rosuvastatin in lowering LDL. Treatment of ...

BARCELONA, Spain – Sunday 31 August: When it comes to cholesterol-lowering statin medications for patients with type 2 diabetes, rosuvastatin may be a better choice than atorvastatin, according to the ...

Rosuvastatin for cholesterol lowering was associated with slightly greater risks for kidney harm than atorvastatin, risks that were greater at higher-dose levels, in a large retrospective cohort study ...

To investigate the efficacy and the safety of the three most commonly prescribed statins rosuvastatin, atorvastatin, and pravastatin zyprexa mg 5 managing dyslipidemia among diabetic patients in Qatar ...

Current international and national guidelines[2,3,4] continue to stress the significance of reducing LDL-cholesterol (LDL-C), an important risk factor for the development and progression of ...

LONDON (MarketWatch) -- AstraZeneca said it's going to launch the first head-to-head study comparing Crestor at 40 milligram doses with Pfizer's Lipitor at 80 milligrams, on the progression of ...